Collectively, these findings suggest that restoring of the GPR35‐TRPV4 association by Thonningianin A or Carfilzomib could effectively prevent aging‐related endothelial dysfunction and vasodilation impairment. This evidence concerns the gene TRPV4 and endothelial dysfunction.